Lv2
120 积分 2024-08-09 加入
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
23小时前
已完结
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
1天前
已完结
Lung cancer survival only increases by a small amount despite recent treatment advances
1个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
3个月前
已完结
[Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors]
6个月前
已完结
Lung neuroendocrine neoplasms: recent progress and persistent challenges
6个月前
已完结
The Warburg effect: a signature of mitochondrial overload
6个月前
已完结
Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactylation
7个月前
已完结
Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
7个月前
已关闭
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
7个月前
已完结
皖公网安备34019202002308
